QuidelOrtho 10-K 18 Feb 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 11, 2022	Jun. 30, 2021
Cover [Abstract]
Title of 12(b) Security	Common stock, $0.001 par value
Entity Incorporation, State or Country Code	DE
Document Transition Report	false
Document Annual Report	true
Entity Registrant Name	QUIDEL CORP
Entity Central Index Key	0000353569
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	QDEL
ICFR Auditor Attestation Flag	true
Amendment Flag	false
Entity Common Stock, Shares Outstanding		41,778,613
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Public Float			$ 4,581,300,641
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Tax Identification Number	94-2573850
Entity Address, Postal Zip Code	92121
Security Exchange Name	NASDAQ
Entity File Number	0-10961
City Area Code	858
Local Phone Number	552-1100
Entity Address, Address Line One	9975 Summers Ridge Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	San Diego, California
Auditor Firm ID	42

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 802,751	$ 489,941
Marketable securities	25,758	0
Accounts receivable, net	377,969	497,688
Inventories	198,765	113,798
Prepaid expenses and other current assets	35,067	40,975
Total current assets	1,440,310	1,142,402
Property, plant and equipment, net	349,202	110,481
Marketable securities, non-current	37,852	0
Right-of-use assets	127,622	100,544
Goodwill	337,021	337,032
Intangible assets, net	98,655	122,431
Deferred tax asset	20,089	44,762
Other non-current assets	19,623	13,512
Total assets	2,430,374	1,871,164
Current liabilities:
Accounts payable	101,492	86,316
Accrued payroll and related expenses	40,385	34,781
Income taxes payable	66,945	127,788
Operating lease liabilities	10,039	7,799
Contingent consideration	5,986	5,987
Deferred consideration	41,945	42,000
Other current liabilities	56,728	32,290
Total current liabilities	323,520	336,961
Operating lease liabilities - non-current	128,556	100,706
Deferred consideration - non-current	36,491	73,951
Contingent consideration - non-current	87	5,909
Other non-current liabilities	12,358	20,934
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at December 31, 2021 and 2020	0	0
Common stock, $.001 par value per share; 97,500 shares authorized; 41,686 and 42,290 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	42	42
Additional paid-in capital	279,768	388,121
Accumulated other comprehensive income (loss)	355	(431)
Retained earnings	1,649,197	944,971
Total stockholders’ equity	1,929,362	1,332,703
Total liabilities and stockholders’ equity	$ 2,430,374	$ 1,871,164

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	97,500,000	97,500,000
Common stock, shares issued	41,686,000	42,290,000
Common stock, shares outstanding	41,686,000	42,290,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Total revenues	$ 1,698,551	$ 1,661,668	$ 534,890
Cost of sales	427,656	312,813	214,085
Gross profit	1,270,895	1,348,855	320,805
Research and development	95,701	84,292	52,553
Sales and marketing	175,325	133,957	111,114
General and administrative	84,247	66,586	52,755
Acquisition and integration costs	9,557	3,694	11,667
Total operating expenses	364,830	288,529	228,089
Operating income	906,065	1,060,326	92,716
Interest and other expense, net	(5,706)	(9,623)	(14,790)
Loss on extinguishment of debt	0	(10,384)	(748)
Total other expense, net	(5,706)	(20,007)	(15,538)
Income before income taxes	900,359	1,040,319	77,178
Provision for income taxes	196,133	230,032	4,257
Net income	$ 704,226	$ 810,287	$ 72,921
Basic earnings per share	$ 16.74	$ 19.24	$ 1.78
Diluted earnings per share	$ 16.43	$ 18.60	$ 1.73
Shares used in basic per share calculation	42,078	42,124	40,860
Shares used in diluted per share calculation	42,874	43,591	43,111

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 704,226	$ 810,287	$ 72,921
Other comprehensive income (loss)
Changes in cumulative translation adjustment, net of tax	(1,588)	2,554	(322)
Changes in unrealized losses from investments, net of tax	(144)	0	0
Net unrealized gains (losses) on derivative instruments	98	(2,993)	716
Reclassification of net realized losses (gains) on derivative instruments included in net income	2,420	471	(718)
Total change in unrealized gains (losses) from cash flow hedges, net of tax	2,518	(2,522)	(2)
Comprehensive income	$ 705,012	$ 810,319	$ 72,597

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated other comprehensive (loss) income	Retained earnings	Convertible Debt	Convertible DebtCommon Stock
Beginning Balance at Dec. 31, 2018	$ 425,584	$ 39	$ 363,921	$ (139)	$ 61,763
Beginning Balance, shares at Dec. 31, 2018		39,386,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	16,799	$ 2	16,797
Issuance of common stock under equity compensation plans, shares		1,152,000
Stock-based compensation expense	12,088		12,088
Issuance of shares in exchange for Convertible Notes	86,428	$ 1	86,427
Issuance of shares in exchange for Convertible Notes, shares							1,497,000
Tax impact from the conversion of Convertible Notes	568		568
Reduction for equity component of Convertible Notes exchanged	(43,516)		(43,516)
Tax withholdings related to vesting of stock-based awards	(10,728)		(10,728)
Tax withholdings related to vesting of stock-based awards, shares		(167,000)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(324)			(324)
Net income	72,921				72,921
Ending Balance at Dec. 31, 2019	559,820	$ 42	425,557	(463)	134,684
Ending Balance, shares at Dec. 31, 2019		41,868,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	10,380	$ 0	10,380
Issuance of common stock under equity compensation plans, shares		490,000
Stock-based compensation expense	18,969		18,969
Issuance of shares in exchange for Convertible Notes	7,230	$ 0	7,230
Issuance of shares in exchange for Convertible Notes, shares						225,955	226,000
Tax impact from the conversion of Convertible Notes	54		54
Derivative liabilities - Convertible Notes elected to settle in cash	(26,180)		(26,180)
Tax withholdings related to vesting of stock-based awards	(4,198)		(4,198)
Tax withholdings related to vesting of stock-based awards, shares		(37,000)
Repurchases of common stock	$ (43,691)	$ 0	(43,691)
Repurchase of common stock, shares	(257,329)	(257,000)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ 32			32
Net income	810,287				810,287
Ending Balance at Dec. 31, 2020	1,332,703	$ 42	388,121	(431)	944,971
Ending Balance, shares at Dec. 31, 2020		42,290,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	9,552	$ 1	9,551
Issuance of common stock under equity compensation plans, shares		534,000
Stock-based compensation expense	22,679		22,679
Tax withholdings related to vesting of stock-based awards	(37,146)		(37,146)
Tax withholdings related to vesting of stock-based awards, shares		(181,000)
Repurchases of common stock	$ (103,438)	$ (1)	(103,437)
Repurchase of common stock, shares	(957,239)	(957,000)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ 786			786
Net income	704,226				704,226
Ending Balance at Dec. 31, 2021	$ 1,929,362	$ 42	$ 279,768	$ 355	$ 1,649,197
Ending Balance, shares at Dec. 31, 2021		41,686,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
OPERATING ACTIVITIES
Net income	$ 704,226	$ 810,287	$ 72,921
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other	54,384	49,089	47,827
Stock-based compensation expense	25,406	21,019	13,252
Impairment loss	0	0	1,481
Amortization of debt discount and deferred issuance costs	403	771	1,582
Change in fair value of acquisition contingencies	217	1,405	1,467
Accretion of interest on deferred consideration	4,485	6,569	8,224
Net change in operating lease right-of-use assets and liabilities	3,012	434	3,964
Change in deferred tax assets and liabilities	24,673	(20,211)	(1,742)
Change in fair value of derivative liabilities - Convertible Notes	0	1,084	0
Payment of accreted interest on contingent and deferred consideration	(8,157)	0	0
Loss on extinguishment of debt	0	10,384	748
Increase (Decrease) in Operating Capital
Accounts receivable	118,852	(402,094)	(36,059)
Inventories	(85,039)	(54,903)	9,143
Prepaid expenses and other current and non-current assets	(13,256)	(14,264)	4,314
Accounts payable	10,446	52,226	2,434
Accrued payroll and related expenses	4,971	16,024	(1,037)
Income taxes payable	(66,688)	137,708	4,175
Other current and non-current liabilities	27,934	14,235	1,791
Net cash provided by operating activities	805,869	629,763	134,485
INVESTING ACTIVITIES
Acquisitions of property, equipment, investments and intangibles	(292,724)	(64,927)	(27,229)
Proceeds from government assistance allocated to fixed assets	36,881	1,605	0
Purchases of marketable securities	(67,448)	0	0
Proceeds from sale of marketable securities	3,761	0	0
Net cash used for investing activities	(319,530)	(63,322)	(27,229)
FINANCING ACTIVITIES
Proceeds from issuance of common stock	7,550	9,613	14,782
Payments on finance lease obligation	(260)	(511)	(371)
Payments of tax withholdings related to vesting of stock-based awards	(37,146)	(4,198)	(10,728)
Payments on Revolving Credit Facility	0	0	(53,188)
Repurchases of common stock	(103,438)	(43,691)	0
Payments on acquisition contingent consideration	(4,740)	(6,044)	(4,044)
Payments of deferred consideration	(35,143)	(42,000)	(44,000)
Payment on Convertible Note and Derivative Liability	0	(43,446)	0
Transaction costs related to debt exchange	0	0	(733)
Net cash used for financing activities	(173,177)	(130,277)	(98,282)
Effect of exchange rate changes on cash	(352)	1,002	106
Net increase in cash and cash equivalents	312,810	437,166	9,080
Cash and cash equivalents, beginning of period	489,941	52,775	43,695
Cash and cash equivalents, at end of period	802,751	489,941	52,775
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for interest	0	480	2,295
Cash paid during the period for income taxes	235,551	109,912	2,189
Purchase of property, equipment and intangibles by incurring current liabilities	10,456	7,160	1,040
Accrued receivable for capital expenditures to be reimbursed under a government contract		15,854
Reduction of other current liabilities upon issuance of restricted share units	2,001	767	2,018
Extinguishment of Convertible Notes through issuance of stock	$ 0	$ 7,230	$ 86,428

Company Operations and Summary

Company Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Company Operations and Summary of Significant Accounting Policies	Company Operations and Summary of Significant Accounting Policies Quidel Corporation (the “Company”) commenced operations in 1979. The Company operates in one business segment that develops, manufactures and markets diagnostic testing solutions. These diagnostic tests are categorized into four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions. The Company currently sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies and wellness screening centers, as well as for individual, non-professional, OTC use. The Company markets its products through a network of distributors and a direct sales force. The accompanying Consolidated Financial Statements of the Company and its subsidiaries have been prepared in accordance with GAAP. Consolidation— The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. Cash equivalents include money market funds and debt securities of high quality institutions. Marketable Securities— The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and US Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more. Accounts Receivable —The Company sells its products directly to hospitals, reference laboratories, retail clinics, pharmacies, as well as to distributors in the US and internationally (see Note 9). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The balance of accounts receivable is net of reserves of $52.4 million and $103.4 million at December 31, 2021 and 2020, respectively, of which the reserve related to contract rebates was $40.3 million and $100.8 million, respectively. Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable. Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss). The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable. Inventories— Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified. Property, Plant and Equipment— Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets ( three Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life. Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 3 for additional discussion of the Convertible Notes issued in December 2014. Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based upon historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively. Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identif ied in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service. During 2021, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of December 31, 2021, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based upon an estimate of total inventory remaining at our retailers which was subject to return. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately . The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument was not material in the years ended December 31, 2021, 2020 and 2019. Government Assistance — During the year ended December 31, 2020, the Company entered into a contract with the NIH, through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments include key deliverables and milestones that directly support the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company will also provide instruments and assays to NIH. There are no refund provisions under the contract. Consideration from the contract is allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there is reasonable assurance the Company will meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays is recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that relates to capital expenditures is recorded as a reduction to the carrying value of such assets and amortized over the useful life of the assets. Consideration allocated to the remainder of the contract is recorded as reductions to the related expense. Amounts billed but not collected as of December 31, 2020 were included in other receivables within prepaid expenses and other current assets. As of December 31, 2021, the Company had achieved and collected payments for all milestones under the NIH contract. Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third-party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred. Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $29.3 million, $14.2 million and $9.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. Advertising Costs— Advertising costs are expensed as incurred. Advertising costs were $13.7 million, $1.1 million and $1.3 million for the years ended December 31, 2021, 2020 and 2019, respectively. Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision. Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820 , Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. The fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for time-based restricted stock units (“RSUs”) is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock units granted are performance-based and vesting is tied to achievement of specific Company goals over a three-year time period, subject to early vesting upon achievement of the performance goals. For purposes of measuring compensation expense for performance-based restricted stock units (“PSUs”), the number of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated. Leases— Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options. For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities. Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, net, other current liabilities and other non-current liabilities. Comprehensive Income —Comprehensive income includes unrealized gains and losses that are related to the cumulative translation adjustments, unrealized gains and losses on marketable securities, and derivative instruments excluded from the Company’s Consolidated Statements of Income. Use of Estimates —The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Periods —Each of the Company’s fiscal quarters ends on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ended January 2, 2022 was 52 weeks and the Company’s fiscal years ended January 3, 2021 and December 29, 2019 were 53 and 52 weeks, respectively. For ease of reference, the calendar year end dates are used herein.

Balance Sheet Account Details (

Balance Sheet Account Details (Notes)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Account Details	Balance Sheet Account Details Marketable securities The following is a summary of marketable securities (in thousands): December 31, 2021 Amortized Cost Gross Unrealized Losses Fair Value Corporate bonds $ 22,344 $ (28) $ 22,316 Asset-backed securities 3,443 (1) 3,442 Total marketable securities, current 25,787 (29) 25,758 Corporate bonds, non-current 26,761 (83) 26,678 Asset-backed securities, non-current 11,197 (23) 11,174 Total marketable securities $ 63,745 $ (135) $ 63,610 Prepaid expenses and other current assets The following is a summary of prepaid expenses and other current assets (in thousands): December 31, 2021 2020 Unbilled receivables $ — $ 16,041 Other receivables 15,879 15,442 Prepaid expenses 14,598 7,335 Other 4,590 2,157 Total prepaid expenses and other current assets $ 35,067 $ 40,975 Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The following is a summary of inventories (in thousands): December 31, 2021 2020 Raw materials $ 103,159 $ 58,264 Work-in-process (materials, labor and overhead) 36,091 31,359 Finished goods (materials, labor and overhead) 59,515 24,175 Total inventories $ 198,765 $ 113,798 Property, Plant and Equipment, net The following is a summary of property, plant and equipment (in thousands): December 31, 2021 2020 Equipment, furniture and fixtures $ 159,008 $ 91,838 Building and improvements 146,784 49,014 Leased instruments 68,062 60,722 Land 10,179 1,080 Construction in Progress 105,247 32,595 Total property, plant and equipment, gross 489,280 235,249 Less: accumulated depreciation and amortization (140,078) (124,768) Total property, plant and equipment, net $ 349,202 $ 110,481 Construction in progress reflects amounts incurred for construction or improvements of property, plant, or equipment that have not been made in service. In addition, construction in progress includes instruments that have not been placed at a customer under a lease agreement that will be reclassified to leased instruments once placed at a customer site. The total e xpense for depreciation of fixed assets and amortization of leasehold improvements was $24.3 million, $20.8 million and $19.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. Maintenance and minor repairs are charged to operations as incurred. Goodwill and Intangible Assets The Company had goodwill of $337.0 million as of December 31, 2021, which remains consistent with December 31, 2020. Finite-lived intangible assets consisted of the following (dollar amounts in thousands): December 31, 2021 December 31, 2020 Description Weighted-average Gross Accumulated Net Gross Accumulated Net Purchased technology 9.1 $ 112,725 $ (78,204) $ 34,521 $ 112,100 $ (71,426) $ 40,674 Customer relationships 7.0 122,690 (77,281) 45,409 122,584 (60,688) 61,896 License agreements 9.9 6,511 (5,658) 853 6,518 (5,312) 1,206 Patent and trademark costs 10.8 28,740 (15,736) 13,004 28,740 (13,038) 15,702 Software development costs 4.6 11,705 (6,837) 4,868 8,743 (5,790) 2,953 Total finite-lived intangible assets $ 282,371 $ (183,716) $ 98,655 $ 278,685 $ (156,254) $ 122,431 Amortization expense related to the capitalized software costs was $1.0 million, $0.9 million and $0.8 million for the years ended December 31, 2021, 2020 and 2019, respectively. Amortization expense (including capitalized software costs) was $27.4 million, $27.3 million and $27.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of December 31, 2021 is as follows (in thousands): For the years ending December 31, Amortization expense 2022 $ 27,897 2023 27,186 2024 22,550 2025 8,230 2026 8,667 Thereafter 4,125 Total $ 98,655 Other current liabilities The following is a summary of other current liabilities (in thousands): December 31, 2021 2020 Customer incentives and rebates $ 15,916 $ 15,663 Accrued other taxes payable 10,218 2,157 Deferred revenue 1,922 3,733 Derivative liabilities 269 3,061 Payables under transition services agreements 10,927 — Other 17,476 7,676 Total other current liabilities $ 56,728 $ 32,290

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes In December 2014, the Company issued $172.5 million aggregate principal amount of Convertible Notes. During 2020, the remaining aggregate principal amount of $13.1 million was settled or matured and as of December 31, 2020 no amounts were outstanding. The following table summarizes the interest expense related to the Convertible Notes for the following periods (in thousands): Year ended December 31, 2020 2019 Amortization of debt discount and deferred issuance costs $ 368 $ 1,179 Coupon interest 195 1,103 Total Interest Expense $ 563 $ 2,282 The following table summarizes information about the settlement of the Convertible Notes during the year ended December 31, 2020 (dollars in thousands): Year ended December 31, 2020 Principal amount settled $ 13,131 Number of shares of common stock issued 225,955 Payment on Convertible Note and Derivative Liability $ 43,446 Revolving Credit Facility On August 31, 2018, the Company entered into the Credit Agreement, which provides the Company with a $175.0 million Revolving Credit Facility. No balance was outstanding as of December 31, 2021 or 2020. The Credit Agreement has a term of five years and matures on August 31, 2023. Loans will bear interest at a rate equal to (i) the London Interbank Offered Rate (“LIBOR”) plus the “applicable rate” or (ii) the “base rate” (defined as the highest of (a) the Bank of America prime rate, (b) the Federal Funds rate plus one-half of one percent and (c) LIBOR plus one percent) plus the “applicable rate.” The applicable rate is determined in accordance with a pricing grid based on the Company’s Consolidated Leverage Ratio (as defined in the Credit Agreement) ranging from 1.75% to 2.50% per annum for LIBOR rate loans and from 0.75% to 1.50% per annum for base rate loans. In addition, the Company pays a commitment fee on the unused portion of the Credit Agreement based on the Company’s Consolidated Leverage Ratio ranging from 0.15% to 0.30% per annum. The Revolving Credit Facility is guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and is secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets, and contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, dividends and other distributions, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) as of the last day of each fiscal quarter of 3.50 to 1.00, which ratio may be increased to 4.50 to 1.00 in case of certain qualifying acquisitions; and (ii) a minimum Consolidated Fixed Charge Coverage Ratio (as defined in the Credit Agreement) of 1.25 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. The Company was in compliance with all financial covenants as of December 31, 2021. Interest expense recognized on the Credit Agreement, including amortization of deferred issuance cost, was $0.7 million, $0.7 million, and $1.7 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Significant components of the provision for income taxes were as follows (in thousands): December 31, 2021 2020 2019 Current: Federal $ 148,827 $ 198,498 $ 1,559 State 42,377 34,608 746 Foreign 2,291 1,136 2,007 Total current provision 193,495 234,242 4,312 Deferred: Federal 7,168 (2,855) 1,234 State (2,540) (1,104) (1,186) Foreign (1,990) (251) (103) Total deferred provision (benefit) 2,638 (4,210) (55) Provision for income taxes $ 196,133 $ 230,032 $ 4,257 The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2021 2020 2019 United States $ 891,261 $ 1,035,752 $ 70,606 Foreign 9,098 4,567 6,572 Income before income taxes $ 900,359 $ 1,040,319 $ 77,178 Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2021 and 2020 are shown below (in thousands): December 31, 2021 2020 Deferred tax assets: Lease liability $ 32,692 $ 24,790 Intangible assets 2,226 2,747 Allowance for returns and discounts 25,661 27,277 Stock-based compensation 9,171 8,367 Tax credit carryforwards 10,697 11,770 Other, net 15,486 10,426 Total deferred tax assets 95,933 85,377 Valuation allowance for deferred tax assets (2,327) (2,281) Total deferred tax assets, net of valuation allowance 93,606 83,096 Deferred tax liabilities: Right-of-use assets (30,114) (22,969) Intangible assets (946) (1,133) Property, plant and equipment (42,457) (14,232) Total deferred tax liabilities (73,517) (38,334) Net deferred tax assets $ 20,089 $ 44,762 Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. For the three years ended December 31, 2021, the Company has demonstrated positive cumulative pre-tax book income. Such objective positive evidence allowed the Company to consider other subjective evidence, such as the Company’s projections for future profitability, to determine the realizability of its deferred tax assets. On the basis of this evaluation, during the year ended December 31, 2021, the valuation allowance did not materially change from the prior year. The valuation allowance of $2.3 million a s of December 31, 2021 represents the portion of the deferred tax asset that management could not conclude was more likely than not to be realized. The amount of the deferred tax assets considered realizable could be adjusted in the future based on changes in available positive and negative evidence. As of December 31, 2021, the Company had no federal net operating loss (“NOL”) carryforwards. The Company had state NOLs of approximately $5.9 million, wh ich will begin to expire in 2030 unless previously utilized. The Company has no federal research credit carryforwards. The Company has federal foreign tax credits of $2.3 million, which will begin to expire on December 31, 2028 unless previously utilized. The Company has state research credits of $11.8 million , of which none expire. Pursuant to Internal Revenue Code Sections 382 and 383, the Company’s use of its NOL and tax credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three-year period. As of December 31, 2021, the Company does not believe any historical ownership change has limited the use of its NOLs or tax credit carryforwards. The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows (in thousands): Year ended December 31, 2021 2020 2019 Tax expense at statutory tax rate $ 189,081 $ 218,467 $ 16,207 State tax expense, net of federal tax 30,147 30,289 1,061 Permanent differences 1,834 3,843 611 Federal and state research credits—current year (7,717) (5,037) (4,269) Stock-based compensation (9,235) (13,867) (10,408) Change in valuation allowance (103) (72) 523 Foreign Derived Intangible Income Deduction (FDII) (8,419) (8,589) (159) Other 545 4,998 691 Provision for income taxes $ 196,133 $ 230,032 $ 4,257 The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2021 2020 2019 Beginning balance $ 22,557 $ 17,236 $ 15,245 Increases (decreases) related to prior year tax positions 478 (2,351) 287 Increases related to current year tax positions 968 7,726 2,209 Decreases from voluntary disclosure agreements (6,338) — — Expiration of statute of limitations for assessment of taxes — (54) (505) Ending balance $ 17,665 $ 22,557 $ 17,236 As of December 31, 2021, 2020 and 2019, the Company had unrecognized tax benefits of $17.7 million, $22.6 million , and $17.2 million, respectively, of wh ich $11.3 million, $15.0 million and $11.1 million, respectively, would reduce the Company’s annual effective tax rate, if recognized. It is reasonabl y possible that the amount of unrecognized tax benefits in various jurisdictions may decrease in the next 12 months due to settlements with tax authorities. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next 12 months cannot be made at this time. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax expense. The Company had accrued interest and penalties associated with uncertain tax positions of $1.2 million as of December 31, 2021, $0.5 million as of December 31, 2020 and $0.4 million as of December 31, 2019. Interest expense, net of accrued interest (reversed) for the years ended December 31, 2021, 2020 and 2019 was approximately $0.7 million , $0.1 million and $0.1 million, respectively. The Company is subject to periodic audits by domestic and foreign tax authorities. As of December 31, 2021, the Company no longer has any federal NOL or credit carryforwards. However, because of utilization of tax attributes generated in tax years 2012 and later on its tax returns still open by statute, the Company’s federal tax years from 2012 and forward are still subject to examination by tax authorities. Due to the carryforward of unutilized California NOLs and credits, the Company’s California tax returns for years 2001 and forward are subject to examination by tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' Equity	Note 5. Stockholders’ Equity Preferred Stock. The Company’s certificate of incorporation, as amended, authorizes the issuance of up to 5.0 million shares of preferred stock. The Board is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. However, the amended certificate of incorporation specifies the initial series and the rights of that series. No shares of preferred stock were outstanding as of December 31, 2021, 2020 or 2019. Equity Incentive Plan. The Company grants stock options, RSUs and PS Us to employees and non-employee directors under its 2018 Equity Incentive Plan (the “2018 Plan”). The Company previously granted stock options under its 2016 Equity Incentive Plan (the “2016 Plan”), Amended and Restated 2010 Equity Incentive Plan (the “2010 Plan”) and the Amended and Restated 2001 Equity Incentive Plan (the “2001 Plan”). The 2016 Plan, 2010 Plan and 2001 Plan were terminated at the time of adoption of the 2018 Plan, but the terminated plans continue to govern outstanding options granted thereunder. The Company has stock options, RSUs and PSUs outstanding, which were issued under each of these equity incentive plans to certain employees and non-employee directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $15.40 to $254.00 per share, and generally vest over four years. As of December 31, 2021, approximately 1.9 million shares of common stock remained available for grant and 3.2 million shares of common stock were reserved for future issuance under the 2018 Plan. Restricted Stock Units. The Company grants b oth RSU s and PSUs to certain officers and directors. Until the restrictions lapse, ownership of the affected RSUs granted to the Company’s officers and directors is conditional upon continuous employment with the Company. For the years ended December 31, 2021, 2020 and 2019, the Company granted approximately 0.1 million, 0.2 million and 0.3 million shares of common stock, respectively, of RSUs to certain officers and directors, which either have a time-based, four-year vesting provision or performance-based vesting provision. During the years ended December 31, 2021, 2020 and 2019, RSUs were granted to certain members of the Board in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants was $0.6 million, $0.5 million and $0.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. Employee Deferred Bonus Compensation Program. For the years ended December 31, 2021, 2020 and 2019, certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the cash value of their cash bonus in the form of fully vested RSUs plus a premium as additional RSUs, issued under the 2018 Plan. The premium RSUs are subject to a one-year vesting requirement from the date of issuance. The additional premium will be determined based on the length of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred. Employee Stock Purchase Plan. Under the ESPP, full-time employees were allowed to purchase common stock through payroll deductions (which could not exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six-month purchase period. As of December 31, 2021, 56,623 shares of common stock remained available for future issuance. Share Repurchase Program. On December 12, 2018, the Board authorized a stock repurchase program, allowing the Company to repurchase up to $50.0 million of its common stock. On August 28, 2020, the Board approved an amendment to the stock repurchase program that authorized repurchases of an additional $150.0 million of the Company’s common stock through August 28, 2022. During the years ended December 31, 2021 and 2020, 957,239 and 257,329 shares of outstanding common stock were repurchased under the Company’s stock repurchase program. As of December 31, 2021, the Company had approximately $52.9 million available under the stock repurchase program.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense was as follows (in thousands): Year ended December 31, 2021 2020 2019 Cost of sales $ 2,665 $ 2,012 $ 1,162 Research and development 4,434 3,372 2,332 Sales and marketing 6,438 6,009 3,497 General and administrative 11,869 9,626 6,261 Total stock-based compensation expense $ 25,406 $ 21,019 $ 13,252 For the years ended December 31, 2021, 2020 and 2019, the Company recorded $3.0 million, $2.2 million and $1.4 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 5. During the years ended December 31, 2021, 2020 and 2019, $2.8 million, $2.1 million and $0.8 million, respectively, were initially recorded as a component of accrued payroll and related expenses associated with the deferred bonus compensation program. Stock Options Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: Year ended December 31, 2021 2020 2019 Risk-free interest rate 0.48 % 1.18 % 2.51 % Expected option life (in years) 4.99 5.12 5.68 Volatility rate 54 % 41 % 39 % Dividend rate 0 % 0 % 0 % The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the US Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations. The Company’s determination of fair value is affected by the Company’s stock price, as well as a number of assumptions that require judgment. The weighted-average fair value per share was $106.55, $36.84 and $23.67 for options granted during the years ended December 31, 2021, 2020 and 2019, respectively. The total intrinsic value was $9.9 million, $51.8 million and $49.8 million for options exercised during the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, total unrecognized compensation expense related to stock options was approximately $8.7 million and the related weighted-average period over which it is expected to be recognized is approximately 1.8 years. The maximum contractual term of the Company’s stock options is ten years. A summary of stock option activity for the years ended December 31, 2019, 2020 and 2021 is as follows (dollars in thousands, except price data): Number Weighted-average exercise price Weighted- Aggregate Outstanding at December 31, 2018 1,877 $ 21.53 Granted 169 59.18 Exercised (1,091) 19.22 Forfeited (11) 49.71 Outstanding at December 31, 2019 944 30.63 Granted 145 96.34 Exercised (317) 21.03 Forfeited (12) 43.34 Outstanding at December 31, 2020 760 46.95 Granted 58 232.75 Exercised (90) 38.28 Forfeited (6) 94.44 Outstanding at December 31, 2021 722 $ 62.71 6.02 $ 59,339 Vested and expected to vest at December 31, 2021 709 $ 61.35 5.98 $ 58,881 Exercisable at December 31, 2021 448 $ 34.51 4.91 $ 45,376 Restricted Stock Units A summary of RSU activity for the years ended December 31, 2019, 2020 and 2021 is as follows (in thousands, except price data): Shares Weighted-average Non-vested at December 31, 2018 676 30.75 Granted 279 59.75 Vested (148) 24.26 Forfeited (21) 43.90 Non-vested at December 31, 2019 786 41.88 Granted 235 101.20 Vested (123) 26.58 Forfeited (20) 58.32 Non-vested at December 31, 2020 878 $ 59.60 Granted 137 $ 188.06 Vested (414) $ 49.00 Forfeited (14) $ 106.11 Non-vested at December 31, 2021 587 $ 95.81 The total amount of unrecognized compensation expense related to non-vested RSUs as of December 31, 2021 was approximately $30.8 million, which is expected to be recognized over a weighted-average period of approximately 1.6 years.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Convertible Notes. Potentially dilutive common shares from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares from the Convertible Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Notes is added back to net income. The Convertible Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Notes became convertible on March 31, 2018 and matured on December 15, 2020. The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods (in thousands): Year ended December 31, 2021 2020 2019 Numerator: Net income used for basic earnings per share $ 704,226 $ 810,287 $ 72,921 Interest expense on Convertible Notes, net of tax — 445 1,848 Net income used for diluted earnings per share, if-converted method $ 704,226 $ 810,732 $ 74,769 Basic weighted-average common shares outstanding 42,078 42,124 40,860 Dilutive potential shares issuable from Convertible Notes — 295 1,062 Dilutive potential shares issuable from stock options and unvested RSUs 796 1,172 1,189 Diluted weighted-average common shares outstanding, if-converted 42,874 43,591 43,111 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 153 10 199

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company leases administrative, research and development, sales and marketing and manufacturing facilities and certain equipment under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases, and may contain clauses for rent escalation, renewal options or early termination. The components of lease expense and supplemental cash flow information related to leases during the respective periods were as follows (in thousands): Year ended December 31, 2021 2020 Finance lease ROU asset amortization $ 282 $ 303 Finance lease interest expense 657 877 Total finance lease costs 939 1,180 Operating lease costs 15,361 11,236 Total lease costs $ 16,300 $ 12,416 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 12,347 $ 10,801 Operating cash flows from finance leases $ 657 $ 877 ROU assets obtained in exchange for new lease liabilities Operating leases $ 37,349 $ 15,271 Finance leases $ — $ — The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2021 were as follows (dollars in thousands): Years ending December 31, Operating Finance 2022 $ 15,468 $ 272 2023 15,529 297 2024 15,639 99 2025 15,736 — 2026 16,057 — Thereafter 116,835 — Total lease payments 195,264 668 Less: imputed interest (38,366) (32) Less: tenant improvement allowance (receipt anticipated in 2022) (18,303) — Total 138,595 636 Less: current portion (10,039) (275) Non-current portion $ 128,556 $ 361 Weighted average remaining lease term 11.7 years 3.3 years Weighted average discount rate 4 % 4 % Summers Ridge Lease — The Company leases three of the four buildings that are located on the Summers Ridge property in San Diego, California with an initial term through January 2033 with options to extend the lease for two additional five-year terms upon satisfaction of certain conditions, which have not been included in the determination of the lease term. The lease is subject to must-take provisions related to one additional building, which will have the same lease term as the three buildings originally leased. The remaining building is subject to the expiration of the lease with its current tenant in October 2022, subject to an option to renew for a two-year period. McKellar Court Lease — During 1999, the Company completed a sale and leaseback transaction of its San Diego facility at McKellar Court to 10165 McKellar Court, L.P. (“McKellar LP” or the “partnership”) for which the Company was the limited partner. McKellar LP owned the real property and improvements located at 10165 McKellar Court (the “McKellar Property”). The partnership was deemed to be a variable interest entity (“VIE”). The Company was not, however, the primary beneficiary of the VIE as it did not have the power to direct the activities of the partnership and did not have the obligation to absorb losses or receive benefits of the partnership that could potentially be significant to the partnership. The Company’s primary use of the McKellar Property is for manufacturing and administrative offices. On August 17, 2021, a wholly owned subsidiary of the Company purchased the general partner’s interest (the “GP interest”) in McKellar LP for a net purchase price of $28.9 million, which was acquired using cash on hand. As a result of the purchase of the GP interest, the partnership is now a wholly owned subsidiary of the Company. The partnership continues to be a VIE for which the Company is now the primary beneficiary. The Company accounted for the GP interest as an asset acquisition and recorded building and land with a total value of $28.9 million. Prior to the purchase date, the Company was leasing the McKellar Property through 2030, with options to extend for two additional five‑year periods. As a result of the Company’s purchase of the GP interest in McKellar LP, the Company no longer makes lease payments for the McKellar Property. Prior to the acquisition, t he Company made lease payments to the partnership of approximately $0.6 million, $1.0 million and $1.0 million for the years ended December 31, 2021, 2020 and 2019, respectively. Rutherford Lease — During January 2021, the Company entered into a lease agreement for a manufacturing facility in Carlsbad, California and recorded a ROU asset and a corresponding lease liability of approximately $39.4 million. The initial lease term is 15 years with options to extend the lease for two additional five-year periods. Purchase Commitments The Company has $3.4 million in firm inventory purchase commitments as of December 31, 2021, the majority of which is expected to be purchased in the next one to three years. Litigation and Other Legal Proceedings In Beckman Coulter, Inc. v. Quidel Corporation, which was filed in the Superior Court for the County of San Diego, California, on November 27, 2017, Beckman alleged that a provision of an agreement between the Company and Beckman violated state antitrust laws. The Company’s acquisition of the BNP Business in October 2017 consisted of assets and liabilities relating to a contractual arrangement with Beckman (the “BNP Supply Agreement”) for the supply of antibodies and other inputs related to, and distribution of, the Triage BNP test for the Beckman Coulter Access Family of Immunoassay Systems. In the lawsuit, Beckman asserted that an exclusivity provision violated certain state antitrust laws and was unenforceable. From the inception of the lawsuit, the lawsuit was subject to numerous motions, rulings, appellate reviews and opinions. The matter was scheduled for trial starting April 15, 2022. On July 24, 2021, the Company and Beckman entered into a Master Agreement (the “Master Agreement”) pursuant to which, among other matters, the Company’s business of selling and distributing the BNP test for the BNP Business will be transitioned to Beckman. Concurrent with entering into the Master Agreement, the Company and Beckman entered into a Settlement Agreement to resolve all disputes relating to the existing BNP Supply Agreement, among other matters. On August 3, 2021, the lawsuit was dismissed with prejudice. As consideration for the arrangements during each of calendar years 2022 through and including 2029, the Company will receive a minimum payment of $70.0 million and a maximum payment of $75.0 million. Such maximum payments were pro-rated for 2021, based on the period commencing on the date of the initial commercial transition to Beckman, through December 31, 2021. In addition, the parties entered into other related agreements under the Master Agreement, including a Transition Services Agreement, pursuant to which the parties will provide various transitional services, a Supply Agreement for the supply by the Company of its antibody and other components used in the manufacture of the BNP test, and a Distribution Agreement, granting Beckman the right to sell and distribute the BNP test as described above. From time to time, the Company is involved in other litigation and legal proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to its business. The Company accrues for legal claims when, and to the extent that, amounts associated with the claims become probable and are reasonably estimable. The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. For those matters as to which the Company is not able to estimate a possible loss or range of loss, the Company is not able to determine whether the loss will have a material adverse effect on its business, financial condition, results of operations or liquidity. No accrual has been recorded as of December 31, 2021 and December 31, 2020 related to such matters as they are not probable and/or reasonably estimable. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. However, the resolution of, or increase in any accruals for, one or more matters may have a material adverse effect on the Company’s results of operations and cash flows. The Company also maintains insurance, including coverage for product liability claims, in amounts that management believes are appropriate given the nature of its business. Licensing Arrangements The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales, as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $2.0 million, $2.4 million and $1.1 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Segment, Revenue and Geographic

Segment, Revenue and Geographic Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment, Revenue and Geographic Information	Segment, Revenue and Geographic Information The Company operates in one reportable segment. Sales to customers outside the US represented 17%, 13% and 33% of total revenue for the years ended December 31, 2021, 2020 and 2019, respectively, of which sales to customers in China comprised 3%, 4% and 13%, respectively. As of December 31, 2021 and 2020, net accounts receivable due from foreign customers were $53.5 million and $18.6 million, respectively. For the years ended December 31, 2021 and 2020, sales of the Company’s COVID-19 products accounted for 75% and 70%, respectively, of total revenue. For the years ended December 31, 2021, 2020 and 2019, sales of the Company’s influenza products accounted for 4%, 8% and 26%, respectively, of total revenue. The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2021 2020 2019 Customer: A 24 % 29 % 13 % B 9 % 16 % 18 % C 9 % 13 % 5 % D 7 % 10 % 15 % 49 % 68 % 51 % As of December 31, 2021 and 2020, net accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $267.3 million and $411.7 million, respectively. The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue 2021 2020 2021 2020 2019 Domestic $ 347,132 $ 108,375 $ 1,415,413 $ 1,452,329 $ 358,381 Foreign 2,070 2,106 283,138 209,339 176,509 Total $ 349,202 $ 110,481 $ 1,698,551 $ 1,661,668 $ 534,890 Consolidated total revenues by product category were as follows (in thousands): Year ended December 31, 2021 2020 2019 Rapid Immunoassay $ 1,197,459 $ 1,144,831 $ 191,736 Cardiometabolic Immunoassay 255,788 242,933 266,505 Molecular Diagnostic Solutions 200,487 222,964 21,716 Specialized Diagnostic Solutions 44,817 50,940 54,933 Total revenues $ 1,698,551 $ 1,661,668 $ 534,890

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2021 December 31, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 204,672 $ 6,649 $ — $ 211,321 $ 200,003 $ — $ — $ 200,003 Marketable securities — 63,610 — 63,610 — — — — Derivative assets — 84 — 84 — 24 — 24 Total assets measured at fair value $ 204,672 $ 70,343 $ — $ 275,015 $ 200,003 $ 24 $ — $ 200,027 Liabilities: Derivative liabilities $ — $ 269 $ — $ 269 $ — $ 3,061 $ — $ 3,061 Contingent consideration — — 6,073 6,073 — — 11,896 11,896 Deferred consideration — 78,436 — 78,436 — 115,951 — 115,951 Total liabilities measured at fair value $ — $ 78,705 $ 6,073 $ 84,778 $ — $ 119,012 $ 11,896 $ 130,908 There were no transfers of assets or liabilities between Level 1, Level 2, and Level 3 categories of the fair value hierarchy during the years ended December 31, 2021 and 2020. Cash equivalents consist of funds held in money market accounts that are valued using quoted prices in active markets for identical instruments and highly liquid corporate debt securities with maturities within three months from purchase. Marketable securities consist of investment-grade corporate debt securities, asset-backed securities and US Treasury securities. Derivative financial instruments are based on observable inputs that are corroborated by market data. Observable inputs include broker quotes, daily market foreign currency rates and forward pricing curves. In connection with the acquisition of the BNP Business, the Company will pay annual installments of up to $48.0 million each through April 2023. The fair value of the deferred consideration is calculated based on the net present value of cash payments using an estimated borrowing rate based on a quoted price for a similar liability. The fair value of the contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculation are a significant assumption that are not observed in the market and, therefore, the resulting fair value represents a Level 3 measurement. The Company assesses the fair value of contingent consideration to be settled in cash related to prior acquisitions using a discounted revenue model. Significant assumptions used in the measurement include revenue projections and discount rates. This fair value measurement of contingent consideration is based on significant inputs not observed in the market and thus represents a Level 3 measurement. The changes in fair value of the contingent consideration during the years ended December 31, 2021, 2020 and 2019 were due to changes in the estimated payments and discounting periods. Changes in estimated fair value of contingent consideration liabilities from December 31, 2018 through December 31, 2021 were as follows (in thousands): Contingent consideration Balance at December 31, 2018 $ 19,112 Cash payments (4,044) Change in estimated fair value, recorded in general and administrative expenses 1,467 Balance at December 31, 2019 16,535 Cash payments (6,044) Change in estimated fair value, recorded in general and administrative expenses 1,405 Balance at December 31, 2020 11,896 Cash payments (6,040) Change in estimated fair value, recorded in general and administrative expenses 217 Balance at December 31, 2021 $ 6,073

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefit Plan	Note 11. Employee Benefit Plan The Company has a defined contribution 401(k) plan (the “401(k) Plan”) covering all employees who are eligible to join the 401(k) Plan upon employment. Employee contributions are subject to a maximum limit by federal law. The 401(k) Plan includes an employer match of 50% on the first 6% of pay contributed by the employee. The Company contributed approximately $3.8 million, $3.1 million and $2.5 million to the 401(k) Plan during the years ended December 31, 2021, 2020 and 2019, respectively.

Foreign Currency Hedges

Foreign Currency Hedges	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign Currency Hedges	Foreign Currency Hedges In the normal course of business, the Company is exposed to gains and losses resulting from fluctuations in foreign currency exchange rates. As part of its strategy to manage the level of exposure to the risk of fluctuations in foreign currency exchange rates, the Company uses designated cash flow hedges in the form of foreign currency forward contracts to mitigate the impact of foreign currency translation on transactions that are denominated primarily in the Euro and the Chinese Yuan. The Company also uses non-designated forward contracts to hedge non-functional currency denominated balance sheet assets. Hedging relationships for all derivative hedges and the underlying hedged items, as well as the risk management objectives and strategies for undertaking the hedge transactions, are formally documented. The Company does not use any derivative financial instruments for trading or other speculative purposes. Such foreign currency forward contracts are carried at fair value in prepaid expenses and other current assets or other current liabilities depending on the unrealized gain or loss position of the hedged contract as of the balance sheet date. Changes in the value of the derivatives are recorded to other comprehensive income (loss) until the underlying hedged item is recognized in earnings, or the derivative no longer qualifies as a highly effective hedge. The cash flows from derivatives treated as hedges are classified in the Consolidated Statements of Cash Flows in the same category as the item being hedged. The notional principal amounts for outstanding derivative instruments provide one measure of the transaction volume outstanding and do not represent the amount of the Company’s exposure to credit or market loss. Credit risk represents the Company’s gross exposure to potential accounting loss on derivative instruments that are outstanding or unsettled if all counterparties failed to perform according to the terms of the contract, based on then-current currency exchange rates at each respective date. The Company generally enters into master netting arrangements that reduce credit risk by permitting net settlement of transactions with the same counterparty. The Company presents its derivative assets and derivative liabilities at their net fair values. The Company does not have any derivative instruments with credit-risk related contingent features that would require it to post collateral. The following table summarizes the fair value and notional amounts of the foreign currency forward contracts as of December 31, 2021 and December 31, 2020 (in thousands): December 31, 2021 December 31, 2020 Notional Amount Fair Value, Net Notional Amount Fair Value, Net Designated cash flow hedges: Prepaid expenses and other current assets $ — $ 84 $ — $ — Other current liabilities $ 17,629 $ 139 $ 38,435 $ 2,819 Non-designated forward contracts: Prepaid expenses and other current assets $ — $ — $ 18,160 $ 24 Other current liabilities $ 15,809 $ 130 $ 23,120 $ 242

Pending Business Combination

Pending Business Combination	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Pending Business Combination	Pending Business Combination On December 22, 2021, the Company entered into the BCA with Ortho, Topco, US Holdco Sub, US Merger Sub and US Holdco Sub 2. Under the terms of the BCA, the Company is entering into the Combinations with Ortho under Topco, a new holding company. The Combinations are expected to be implemented by way of (i) the Ortho Scheme, pursuant to which each issued and outstanding Ortho Share will be acquired by a nominee of Topco, such that Ortho will become a wholly owned subsidiary of Topco, and (ii) the Quidel Merger immediately following consummation of the Ortho Scheme, with the Company surviving the merger as a wholly owned subsidiary of Topco. At the effective time of the Ortho Scheme, each Ortho Share will be acquired by a nominee on behalf and for the benefit of Topco in exchange for 0.1055 Topco Shares and $7.14 in cash. At the effective time of the Quidel Merger, each Quidel Share will be converted into the right to receive one Topco Share. Ortho will be acquired for total consideration of approximately $4.3 billion (which is based on the February 9, 2022 closing price of $97.64 per Quidel Share), including $1.75 billion of cash, funded through cash on the Company’s balance sheet and expected incremental borrowings. Following the closing of the Combinations, Ortho’s current net debt of $2.1 billion is expected to continue to be outstanding.

Consolidated Valuation and Qual

Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Consolidated Valuation and Qualifying Accounts	SCHEDULE II QUIDEL CORPORATION CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS Description Balance at Additions charged to expense or as reductions to revenue (1) Deductions (2) Balance at end of (in thousands) Year ended December 31, 2021: Accounts receivable allowance $ 103,435 $ 456,237 $ (507,249) $ 52,423 Year ended December 31, 2020: Accounts receivable allowance $ 15,960 $ 276,988 $ (189,513) $ 103,435 Year ended December 31, 2019: Accounts receivable allowance $ 11,979 $ 65,649 $ (61,668) $ 15,960 (1) Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expense. (2) The deductions represent actual charges against the accrual described above.

Company Operations and Summar_2

Company Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Consolidation	Consolidation— The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. Cash equivalents include money market funds and debt securities of high quality institutions. Marketable Securities— The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and US Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more.
Accounts Receivable	Accounts Receivable —The Company sells its products directly to hospitals, reference laboratories, retail clinics, pharmacies, as well as to distributors in the US and internationally (see Note 9). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The balance of accounts receivable is net of reserves of $52.4 million and $103.4 million at December 31, 2021 and 2020, respectively, of which the reserve related to contract rebates was $40.3 million and $100.8 million, respectively.
Concentration of Credit Risk	Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable. Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss). The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories	Inventories—Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified.
Property, Plant and Equipment	Property, Plant and Equipment—Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets ( three
Intangible Assets	Goodwill and Intangible Assets—Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life.
Convertible Debt	Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 3 for additional discussion of the Convertible Notes issued in December 2014.
Revenue Recognition	Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based upon historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively. Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identif ied in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service. During 2021, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of December 31, 2021, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based upon an estimate of total inventory remaining at our retailers which was subject to return. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately .
Government Assistance	Government Assistance — During the year ended December 31, 2020, the Company entered into a contract with the NIH, through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments include key deliverables and milestones that directly support the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company will also provide instruments and assays to NIH. There are no refund provisions under the contract.
Research and Development Costs	Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third-party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Product Shipment Costs	Product Shipment Costs—Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Income.
Advertising Costs	Advertising Costs—Advertising costs are expensed as incurred.
Income Taxes	Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820 , Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.
Stock-Based Compensation	Stock-Based Compensation—Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. The fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for time-based restricted stock units (“RSUs”) is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock units granted are performance-based and vesting is tied to achievement of specific Company goals over a three-year time period, subject to early vesting upon achievement of the performance goals. For purposes of measuring compensation expense for performance-based restricted stock units (“PSUs”), the number of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated.
Lessee, Operating Leases	Leases— Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options. For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities. Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, net, other current liabilities and other non-current liabilities.
Comprehensive (Loss) Income	Comprehensive Income —Comprehensive income includes unrealized gains and losses that are related to the cumulative translation adjustments, unrealized gains and losses on marketable securities, and derivative instruments excluded from the Company’s Consolidated Statements of Income.
Use of Estimates	Use of Estimates —The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods	Accounting Periods —Each of the Company’s fiscal quarters ends on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ended January 2, 2022 was 52 weeks and the Company’s fiscal years ended January 3, 2021 and December 29, 2019 were 53 and 52 weeks, respectively. For ease of reference, the calendar year end dates are used herein.

Earnings Per Share (Policies)

Earnings Per Share (Policies)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share, Policy [Policy Text Block]	Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Convertible Notes. Potentially dilutive common shares from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares from the Convertible Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Notes is added back to net income. The Convertible Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Notes became convertible on March 31, 2018 and matured on December 15, 2020.

Balance Sheet Account Details_2

Balance Sheet Account Details (Tables)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Marketable Securities	The following is a summary of marketable securities (in thousands): December 31, 2021 Amortized Cost Gross Unrealized Losses Fair Value Corporate bonds $ 22,344 $ (28) $ 22,316 Asset-backed securities 3,443 (1) 3,442 Total marketable securities, current 25,787 (29) 25,758 Corporate bonds, non-current 26,761 (83) 26,678 Asset-backed securities, non-current 11,197 (23) 11,174 Total marketable securities $ 63,745 $ (135) $ 63,610
Schedule of Other Current Assets	The following is a summary of prepaid expenses and other current assets (in thousands): December 31, 2021 2020 Unbilled receivables $ — $ 16,041 Other receivables 15,879 15,442 Prepaid expenses 14,598 7,335 Other 4,590 2,157 Total prepaid expenses and other current assets $ 35,067 $ 40,975
Summary of Inventories	The following is a summary of inventories (in thousands): December 31, 2021 2020 Raw materials $ 103,159 $ 58,264 Work-in-process (materials, labor and overhead) 36,091 31,359 Finished goods (materials, labor and overhead) 59,515 24,175 Total inventories $ 198,765 $ 113,798
Property, Plant and Equipment	The following is a summary of property, plant and equipment (in thousands): December 31, 2021 2020 Equipment, furniture and fixtures $ 159,008 $ 91,838 Building and improvements 146,784 49,014 Leased instruments 68,062 60,722 Land 10,179 1,080 Construction in Progress 105,247 32,595 Total property, plant and equipment, gross 489,280 235,249 Less: accumulated depreciation and amortization (140,078) (124,768) Total property, plant and equipment, net $ 349,202 $ 110,481
Summary of Intangible Assets	Finite-lived intangible assets consisted of the following (dollar amounts in thousands): December 31, 2021 December 31, 2020 Description Weighted-average Gross Accumulated Net Gross Accumulated Net Purchased technology 9.1 $ 112,725 $ (78,204) $ 34,521 $ 112,100 $ (71,426) $ 40,674 Customer relationships 7.0 122,690 (77,281) 45,409 122,584 (60,688) 61,896 License agreements 9.9 6,511 (5,658) 853 6,518 (5,312) 1,206 Patent and trademark costs 10.8 28,740 (15,736) 13,004 28,740 (13,038) 15,702 Software development costs 4.6 11,705 (6,837) 4,868 8,743 (5,790) 2,953 Total finite-lived intangible assets $ 282,371 $ (183,716) $ 98,655 $ 278,685 $ (156,254) $ 122,431
Summary of Expected Future Annual Amortization Expense	The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of December 31, 2021 is as follows (in thousands): For the years ending December 31, Amortization expense 2022 $ 27,897 2023 27,186 2024 22,550 2025 8,230 2026 8,667 Thereafter 4,125 Total $ 98,655
Schedule of Other Current Liabilities	The following is a summary of other current liabilities (in thousands): December 31, 2021 2020 Customer incentives and rebates $ 15,916 $ 15,663 Accrued other taxes payable 10,218 2,157 Deferred revenue 1,922 3,733 Derivative liabilities 269 3,061 Payables under transition services agreements 10,927 — Other 17,476 7,676 Total other current liabilities $ 56,728 $ 32,290

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Summarized Interest Expense	The following table summarizes the interest expense related to the Convertible Notes for the following periods (in thousands): Year ended December 31, 2020 2019 Amortization of debt discount and deferred issuance costs $ 368 $ 1,179 Coupon interest 195 1,103 Total Interest Expense $ 563 $ 2,282
Schedule of Extinguishment of Debt	The following table summarizes information about the settlement of the Convertible Notes during the year ended December 31, 2020 (dollars in thousands): Year ended December 31, 2020 Principal amount settled $ 13,131 Number of shares of common stock issued 225,955 Payment on Convertible Note and Derivative Liability $ 43,446

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of (Benefit) Provision for Income Taxes	Significant components of the provision for income taxes were as follows (in thousands): December 31, 2021 2020 2019 Current: Federal $ 148,827 $ 198,498 $ 1,559 State 42,377 34,608 746 Foreign 2,291 1,136 2,007 Total current provision 193,495 234,242 4,312 Deferred: Federal 7,168 (2,855) 1,234 State (2,540) (1,104) (1,186) Foreign (1,990) (251) (103) Total deferred provision (benefit) 2,638 (4,210) (55) Provision for income taxes $ 196,133 $ 230,032 $ 4,257
Schedule of Income before (Benefit) Provision for Income Taxes	The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2021 2020 2019 United States $ 891,261 $ 1,035,752 $ 70,606 Foreign 9,098 4,567 6,572 Income before income taxes $ 900,359 $ 1,040,319 $ 77,178
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2021 and 2020 are shown below (in thousands): December 31, 2021 2020 Deferred tax assets: Lease liability $ 32,692 $ 24,790 Intangible assets 2,226 2,747 Allowance for returns and discounts 25,661 27,277 Stock-based compensation 9,171 8,367 Tax credit carryforwards 10,697 11,770 Other, net 15,486 10,426 Total deferred tax assets 95,933 85,377 Valuation allowance for deferred tax assets (2,327) (2,281) Total deferred tax assets, net of valuation allowance 93,606 83,096 Deferred tax liabilities: Right-of-use assets (30,114) (22,969) Intangible assets (946) (1,133) Property, plant and equipment (42,457) (14,232) Total deferred tax liabilities (73,517) (38,334) Net deferred tax assets $ 20,089 $ 44,762
Reconciliation of Income Tax Computed at Federal Statutory Rate	The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows (in thousands): Year ended December 31, 2021 2020 2019 Tax expense at statutory tax rate $ 189,081 $ 218,467 $ 16,207 State tax expense, net of federal tax 30,147 30,289 1,061 Permanent differences 1,834 3,843 611 Federal and state research credits—current year (7,717) (5,037) (4,269) Stock-based compensation (9,235) (13,867) (10,408) Change in valuation allowance (103) (72) 523 Foreign Derived Intangible Income Deduction (FDII) (8,419) (8,589) (159) Other 545 4,998 691 Provision for income taxes $ 196,133 $ 230,032 $ 4,257
Summary of Unrecognized Tax Benefits	The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2021 2020 2019 Beginning balance $ 22,557 $ 17,236 $ 15,245 Increases (decreases) related to prior year tax positions 478 (2,351) 287 Increases related to current year tax positions 968 7,726 2,209 Decreases from voluntary disclosure agreements (6,338) — — Expiration of statute of limitations for assessment of taxes — (54) (505) Ending balance $ 17,665 $ 22,557 $ 17,236

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Compensation Expense Related to Stock-Based Compensation Plans	Stock-based compensation expense was as follows (in thousands): Year ended December 31, 2021 2020 2019 Cost of sales $ 2,665 $ 2,012 $ 1,162 Research and development 4,434 3,372 2,332 Sales and marketing 6,438 6,009 3,497 General and administrative 11,869 9,626 6,261 Total stock-based compensation expense $ 25,406 $ 21,019 $ 13,252
Estimated Fair Value of Each Stock Option Award	The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions: Year ended December 31, 2021 2020 2019 Risk-free interest rate 0.48 % 1.18 % 2.51 % Expected option life (in years) 4.99 5.12 5.68 Volatility rate 54 % 41 % 39 % Dividend rate 0 % 0 % 0 %
Summary of Status of Stock Option Activity	A summary of stock option activity for the years ended December 31, 2019, 2020 and 2021 is as follows (dollars in thousands, except price data): Number Weighted-average exercise price Weighted- Aggregate Outstanding at December 31, 2018 1,877 $ 21.53 Granted 169 59.18 Exercised (1,091) 19.22 Forfeited (11) 49.71 Outstanding at December 31, 2019 944 30.63 Granted 145 96.34 Exercised (317) 21.03 Forfeited (12) 43.34 Outstanding at December 31, 2020 760 46.95 Granted 58 232.75 Exercised (90) 38.28 Forfeited (6) 94.44 Outstanding at December 31, 2021 722 $ 62.71 6.02 $ 59,339 Vested and expected to vest at December 31, 2021 709 $ 61.35 5.98 $ 58,881 Exercisable at December 31, 2021 448 $ 34.51 4.91 $ 45,376
Summary of Status of Stock Awards Activity	A summary of RSU activity for the years ended December 31, 2019, 2020 and 2021 is as follows (in thousands, except price data): Shares Weighted-average Non-vested at December 31, 2018 676 30.75 Granted 279 59.75 Vested (148) 24.26 Forfeited (21) 43.90 Non-vested at December 31, 2019 786 41.88 Granted 235 101.20 Vested (123) 26.58 Forfeited (20) 58.32 Non-vested at December 31, 2020 878 $ 59.60 Granted 137 $ 188.06 Vested (414) $ 49.00 Forfeited (14) $ 106.11 Non-vested at December 31, 2021 587 $ 95.81

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods (in thousands): Year ended December 31, 2021 2020 2019 Numerator: Net income used for basic earnings per share $ 704,226 $ 810,287 $ 72,921 Interest expense on Convertible Notes, net of tax — 445 1,848 Net income used for diluted earnings per share, if-converted method $ 704,226 $ 810,732 $ 74,769 Basic weighted-average common shares outstanding 42,078 42,124 40,860 Dilutive potential shares issuable from Convertible Notes — 295 1,062 Dilutive potential shares issuable from stock options and unvested RSUs 796 1,172 1,189 Diluted weighted-average common shares outstanding, if-converted 42,874 43,591 43,111 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 153 10 199
Schedule of Earnings Per Share, Basic and Diluted	The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods (in thousands): Year ended December 31, 2021 2020 2019 Numerator: Net income used for basic earnings per share $ 704,226 $ 810,287 $ 72,921 Interest expense on Convertible Notes, net of tax — 445 1,848 Net income used for diluted earnings per share, if-converted method $ 704,226 $ 810,732 $ 74,769 Basic weighted-average common shares outstanding 42,078 42,124 40,860 Dilutive potential shares issuable from Convertible Notes — 295 1,062 Dilutive potential shares issuable from stock options and unvested RSUs 796 1,172 1,189 Diluted weighted-average common shares outstanding, if-converted 42,874 43,591 43,111 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 153 10 199

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Components of Lease Expense and Supplemental Cash Flow Information	The components of lease expense and supplemental cash flow information related to leases during the respective periods were as follows (in thousands): Year ended December 31, 2021 2020 Finance lease ROU asset amortization $ 282 $ 303 Finance lease interest expense 657 877 Total finance lease costs 939 1,180 Operating lease costs 15,361 11,236 Total lease costs $ 16,300 $ 12,416 Cash paid for amounts included in the measurement of operating lease liabilities Operating cash flows from operating leases $ 12,347 $ 10,801 Operating cash flows from finance leases $ 657 $ 877 ROU assets obtained in exchange for new lease liabilities Operating leases $ 37,349 $ 15,271 Finance leases $ — $ —
Commitments for Minimum Rentals under Non-cancelable Operating Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2021 were as follows (dollars in thousands): Years ending December 31, Operating Finance 2022 $ 15,468 $ 272 2023 15,529 297 2024 15,639 99 2025 15,736 — 2026 16,057 — Thereafter 116,835 — Total lease payments 195,264 668 Less: imputed interest (38,366) (32) Less: tenant improvement allowance (receipt anticipated in 2022) (18,303) — Total 138,595 636 Less: current portion (10,039) (275) Non-current portion $ 128,556 $ 361 Weighted average remaining lease term 11.7 years 3.3 years Weighted average discount rate 4 % 4 %
Commitments for Minimum Rentals under Non-cancelable Finance Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2021 were as follows (dollars in thousands): Years ending December 31, Operating Finance 2022 $ 15,468 $ 272 2023 15,529 297 2024 15,639 99 2025 15,736 — 2026 16,057 — Thereafter 116,835 — Total lease payments 195,264 668 Less: imputed interest (38,366) (32) Less: tenant improvement allowance (receipt anticipated in 2022) (18,303) — Total 138,595 636 Less: current portion (10,039) (275) Non-current portion $ 128,556 $ 361 Weighted average remaining lease term 11.7 years 3.3 years Weighted average discount rate 4 % 4 %

Segment, Revenue and Geograph_2

Segment, Revenue and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Sales to Individual Customers in Excess of 10% of Total Revenue	The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2021 2020 2019 Customer: A 24 % 29 % 13 % B 9 % 16 % 18 % C 9 % 13 % 5 % D 7 % 10 % 15 % 49 % 68 % 51 %
Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue 2021 2020 2021 2020 2019 Domestic $ 347,132 $ 108,375 $ 1,415,413 $ 1,452,329 $ 358,381 Foreign 2,070 2,106 283,138 209,339 176,509 Total $ 349,202 $ 110,481 $ 1,698,551 $ 1,661,668 $ 534,890
Consolidated Net Product Revenues by Disease State	Consolidated total revenues by product category were as follows (in thousands): Year ended December 31, 2021 2020 2019 Rapid Immunoassay $ 1,197,459 $ 1,144,831 $ 191,736 Cardiometabolic Immunoassay 255,788 242,933 266,505 Molecular Diagnostic Solutions 200,487 222,964 21,716 Specialized Diagnostic Solutions 44,817 50,940 54,933 Total revenues $ 1,698,551 $ 1,661,668 $ 534,890

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2021 December 31, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 204,672 $ 6,649 $ — $ 211,321 $ 200,003 $ — $ — $ 200,003 Marketable securities — 63,610 — 63,610 — — — — Derivative assets — 84 — 84 — 24 — 24 Total assets measured at fair value $ 204,672 $ 70,343 $ — $ 275,015 $ 200,003 $ 24 $ — $ 200,027 Liabilities: Derivative liabilities $ — $ 269 $ — $ 269 $ — $ 3,061 $ — $ 3,061 Contingent consideration — — 6,073 6,073 — — 11,896 11,896 Deferred consideration — 78,436 — 78,436 — 115,951 — 115,951 Total liabilities measured at fair value $ — $ 78,705 $ 6,073 $ 84,778 $ — $ 119,012 $ 11,896 $ 130,908
Changes in Estimated Fair Value of Contingent Consideration Liabilities	Changes in estimated fair value of contingent consideration liabilities from December 31, 2018 through December 31, 2021 were as follows (in thousands): Contingent consideration Balance at December 31, 2018 $ 19,112 Cash payments (4,044) Change in estimated fair value, recorded in general and administrative expenses 1,467 Balance at December 31, 2019 16,535 Cash payments (6,044) Change in estimated fair value, recorded in general and administrative expenses 1,405 Balance at December 31, 2020 11,896 Cash payments (6,040) Change in estimated fair value, recorded in general and administrative expenses 217 Balance at December 31, 2021 $ 6,073

Foreign Currency Hedges (Tables

Foreign Currency Hedges (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Assets at Fair Value	The following table summarizes the fair value and notional amounts of the foreign currency forward contracts as of December 31, 2021 and December 31, 2020 (in thousands): December 31, 2021 December 31, 2020 Notional Amount Fair Value, Net Notional Amount Fair Value, Net Designated cash flow hedges: Prepaid expenses and other current assets $ — $ 84 $ — $ — Other current liabilities $ 17,629 $ 139 $ 38,435 $ 2,819 Non-designated forward contracts: Prepaid expenses and other current assets $ — $ — $ 18,160 $ 24 Other current liabilities $ 15,809 $ 130 $ 23,120 $ 242

Company Operations and Summar_3

Company Operations and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments | segment	1
Cash and cash equivalents maximum maturity period	3 months
Allowance receivables	$ 52,400	$ 103,400
Allowance receivables, contract rebates	40,300	100,800
Costs and Expenses	364,830	288,529	$ 228,089
Contract Consideration	65,000
Unbilled Contracts Receivable	$ 0	16,041
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of the assets	3 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of the assets	15 years
Shipping and Handling
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Costs and Expenses	$ 29,300	14,200	9,500
Advertising
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Costs and Expenses	$ 13,700	$ 1,100	$ 1,300

Balance Sheet Account Details -

Balance Sheet Account Details - Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Marketable Securities, Current	$ 25,758	$ 0
Marketable Securities, Noncurrent	37,852	0
Total marketable securities	63,610	$ 0
Short-term Investments
Marketable Securities [Line Items]
Amortized Cost	25,787
Gross Unrealized Losses	(29)
Long-Term Investments
Marketable Securities [Line Items]
Amortized Cost	63,745
Gross Unrealized Losses	(135)
Corporate Debt Securities
Marketable Securities [Line Items]
Marketable Securities, Current	22,316
Marketable Securities, Noncurrent	26,678
Corporate Debt Securities | Short-term Investments
Marketable Securities [Line Items]
Amortized Cost	22,344
Gross Unrealized Losses	(28)
Corporate Debt Securities | Long-Term Investments
Marketable Securities [Line Items]
Amortized Cost	26,761
Gross Unrealized Losses	(83)
Asset-backed Securities
Marketable Securities [Line Items]
Marketable Securities, Current	3,442
Marketable Securities, Noncurrent	11,174
Asset-backed Securities | Short-term Investments
Marketable Securities [Line Items]
Amortized Cost	3,443
Gross Unrealized Losses	(1)
Asset-backed Securities | Long-Term Investments
Marketable Securities [Line Items]
Amortized Cost	11,197
Gross Unrealized Losses	$ (23)

Balance Sheet Account Details_3

Balance Sheet Account Details - Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Offsetting [Abstract]
Unbilled Contracts Receivable	$ 0	$ 16,041
Receivables under transition service agreements	15,879	15,442
Prepaid expenses	14,598	7,335
Other	4,590	2,157
Prepaid expenses and other current assets	$ 35,067	$ 40,975

Balance Sheet Account Details_4

Balance Sheet Account Details - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 103,159	$ 58,264
Work-in-process (materials, labor and overhead)	36,091	31,359
Finished goods (materials, labor and overhead)	59,515	24,175
Total inventories	$ 198,765	$ 113,798

Balance Sheet Account Details_5

Balance Sheet Account Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 489,280	$ 235,249
Less: accumulated depreciation and amortization	(140,078)	(124,768)
Property, Plant and Equipment, Net	349,202	110,481
Depreciation and amortization	24,300	20,800	$ 19,400
Equipment, furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	159,008	91,838
Building and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	146,784	49,014
Leased instruments
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	68,062	60,722
Land
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	10,179	1,080
Construction in Progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 105,247	$ 32,595

Balance Sheet Account Details_6

Balance Sheet Account Details - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Depreciation and amortization	$ 24,300	$ 20,800	$ 19,400
Amortization of Intangible Assets	27,400	27,300	27,500
Goodwill	337,021	337,032
Capitalized Software Cost
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 1,000	$ 900	$ 800

Balance Sheet Account Details_7

Balance Sheet Account Details - Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross assets	$ 282,371	$ 278,685
Accumulated amortization	(183,716)	(156,254)
Total	$ 98,655	122,431
Purchased technology
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	9 years 1 month 6 days
Gross assets	$ 112,725	112,100
Accumulated amortization	(78,204)	(71,426)
Total	$ 34,521	40,674
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	7 years
Gross assets	$ 122,690	122,584
Accumulated amortization	(77,281)	(60,688)
Total	$ 45,409	61,896
License agreements
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	9 years 10 months 24 days
Gross assets	$ 6,511	6,518
Accumulated amortization	(5,658)	(5,312)
Total	$ 853	1,206
Patent and trademark costs
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	10 years 9 months 18 days
Gross assets	$ 28,740	28,740
Accumulated amortization	(15,736)	(13,038)
Total	$ 13,004	15,702
Software development costs
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)	4 years 7 months 6 days
Gross assets	$ 11,705	8,743
Accumulated amortization	(6,837)	(5,790)
Total	$ 4,868	$ 2,953

Balance Sheet Account Details_8

Balance Sheet Account Details - Future annual amortization expense (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
2022	$ 27,897
2023	27,186
2024	22,550
2025	8,230
2026	8,667
Thereafter	4,125
Total	$ 98,655	$ 122,431

Balance Sheet Account Details_9

Balance Sheet Account Details - Other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Offsetting [Abstract]
Customer incentives and rebates	$ 15,916	$ 15,663
Accrued other taxes payable	10,218	2,157
Deferred revenue	1,922	3,733
Derivative liabilities	269	3,061
Payables under transition services agreements	10,927	0
Other	17,476	7,676
Total other current liabilities	$ 56,728	$ 32,290

Debt - Convertible Senior Notes

Debt - Convertible Senior Notes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2016
Convertible Debt
Debt Instrument [Line Items]
Convertible Senior Notes, face amount		$ 172,500,000
Convertible Debt
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 13,131,000

Debt - Summarized Interest Expe

Debt - Summarized Interest Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total Interest Expense	$ 563	$ 2,282
Convertible Debt | 3.25% Convertible Senior Notes due 2020
Debt Instrument [Line Items]
Amortization of debt discount and deferred issuance costs	368	1,179
Coupon interest	$ 195	$ 1,103

Debt - Schedule of Extinguishme

Debt - Schedule of Extinguishment of Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Extinguishment of Debt [Line Items]
Payment on Convertible Note and Derivative Liability	$ 0	$ 43,446	$ 0
Convertible Debt
Extinguishment of Debt [Line Items]
Principal amount settled		$ 13,131
Number of shares of common stock issued		225,955
Payment on Convertible Note and Derivative Liability		$ 43,446

Debt - Credit Agreement (Detail

Debt - Credit Agreement (Details) - USD ($)	Aug. 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 175,000,000
Line of Credit Facility, Commitment Fee Percentage	0.15%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.30%
Number Of Financial Covenants	2
Consolidated Leverage Ratio	3.50
Consolidated Fixed Charge Coverage Ratio	1.25
Total Interest Expense			$ 563,000	$ 2,282,000
Fed Funds Effective Rate Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.005%
Minimum | Base Rate
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	0.75%
Minimum | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	1.75%
Maximum
Debt Instrument [Line Items]
Consolidated Leverage Ratio	4.50
Maximum | Base Rate
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	1.50%
Maximum | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin	2.50%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Term		5 years
Total Interest Expense		$ 700,000	$ 700,000	$ 1,700,000

Income Taxes - Components of (B

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 148,827	$ 198,498	$ 1,559
State	42,377	34,608	746
Foreign	2,291	1,136	2,007
Total current provision	193,495	234,242	4,312
Deferred:
Federal	7,168	(2,855)	1,234
State	(2,540)	(1,104)	(1,186)
Foreign	(1,990)	(251)	(103)
Total deferred provision (benefit)	2,638	(4,210)	(55)
Provision for income taxes	196,133	230,032	4,257
Accrued interest and penalties associated with uncertain tax positions	$ 1,200	$ 500	$ 400

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
United States	$ 891,261	$ 1,035,752	$ 70,606
Foreign	9,098	4,567	6,572
Income before income taxes	$ 900,359	$ 1,040,319	$ 77,178

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Lease liability	$ 32,692	$ 24,790
Intangible assets	2,226	2,747
Allowance for returns and discounts	25,661	27,277
Stock-based compensation	9,171	8,367
Tax credit carryforwards	10,697	11,770
Other, net	15,486	10,426
Total deferred tax assets	95,933	85,377
Valuation allowance for deferred tax assets	(2,327)	(2,281)
Total deferred tax assets	93,606	83,096
Deferred tax liabilities:
Right-of-use assets	(30,114)	(22,969)
Intangible assets	(946)	(1,133)
Property, plant and equipment	(42,457)	(14,232)
Deferred Tax Liabilities, Gross	(73,517)	(38,334)
Net deferred tax assets	$ 20,089	$ 44,762

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Taxes Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 2,327,000	$ 2,281,000
Unrecognized Tax Benefits	17,665,000	22,557,000	$ 17,236,000	$ 15,245,000
Federal Net Operating Loss carryforwards	0
State Net Operating Loss carryforwards	5,900,000
Federal foreign tax credits	2,300,000
Gross research credits	$ 7,717,000	5,037,000	4,269,000
Cumulative changes in ownership percentage	50.00%
Cumulative Change In Ownership Period	3 years
Realized upon settlement	50.00%
Unrecognized tax benefits that would impact effective tax rate	$ 11,300,000	15,000,000	11,100,000
Accrued interest and penalties associated with uncertain tax positions	1,200,000	500,000	400,000
Interest expense, net of accrued interest reversed	700,000	$ 100,000	$ 100,000
Federal research credits
Income Taxes Disclosure [Line Items]
Federal research credits	0
Gross State Research Credits
Income Taxes Disclosure [Line Items]
State research credit - no expiry	$ 11,800,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax expense at statutory tax rate	$ 189,081	$ 218,467	$ 16,207
State tax expense, net of federal tax	30,147	30,289	1,061
Permanent differences	1,834	3,843	611
Federal and state research credits—current year	(7,717)	(5,037)	(4,269)
Stock-based compensation	(9,235)	(13,867)	(10,408)
Change in valuation allowance	(103)	(72)	523
Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount	(8,419)	(8,589)	(159)
Other	545	4,998	691
Provision for income taxes	$ 196,133	$ 230,032	$ 4,257

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 22,557	$ 17,236	$ 15,245
Decreases related to prior year tax positions		(2,351)
Increases related to prior year tax positions	478		287
Increases related to current year tax positions	968	7,726	2,209
Decreases from voluntary disclosure agreements	(6,338)	0	0
Expiration of statute of limitations for assessment of taxes	0	(54)	(505)
Ending balance	$ 17,665	$ 22,557	$ 17,236

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Aug. 28, 2020	Dec. 12, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Weighted- average remaining contractual term, exercisable (in years)	4 years 10 months 28 days
Available for future grant, (in shares)	1,900,000
Common Stock, Capital Shares Reserved for Future Issuance	3,200,000
Restricted stock granted (in shares)	137,000	235,000	279,000
Share-based compensation expense recognized	$ 25,406	$ 21,019	$ 13,252
Deferred period of grants (Condition 1)	1 year
Percentage of premium on amount deferred (Condition 1)	10.00%
Deferred period of grants (Condition 2)	2 years
Percentage of premium on amount deferred (Condition 2)	20.00%
Length Of Time Of Deferral Period Under Condition Three	4 years
Percentage of premium on amount deferred (Condition 3)	30.00%
Minimum percentage of common stock under payroll deductions	10.00%
Fair value of payroll deductions	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period	6 months
Capital shares reserved for future issuance (In shares)	56,623
Payments for repurchase of common stock	$ 103,438	43,691	$ 0
Stock-based compensation expense	$ 103,438	$ 43,691
Authorized stock repurchase program amount				$ 150,000	$ 50,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	52,900,000
Stock Repurchased During Period, Shares	957,239	257,329
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted- average remaining contractual term, exercisable (in years)	10 years
Performance-based vesting period	4 years
Restricted stock granted (in shares)	100,000	200,000	300,000
Employee Deferred Bonus Compensation Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 3,000	$ 2,200	$ 1,400
Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 600	$ 500	$ 500
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in usd per share)	$ 15.40
Percentage of deferred cash bonus	50.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in usd per share)	$ 254
Percentage of deferred cash bonus	100.00%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 25,406	$ 21,019	$ 13,252
Weighted-average grant date fair value of stock options granted (in dollars per share)	$ 106.55	$ 36.84	$ 23.67
Total intrinsic value for options exercised	$ 9,900	$ 51,800	$ 49,800
Total unrecognized compensation expense related to non-vested stock options	$ 8,700
Expected weighted-average period of recognition for unrecognized compensation expense	1 year 9 months 18 days
Maximum contractual term	10 years
Deferred bonus compensation program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 3,000	2,200	1,400
Recorded as a component of accrued payroll and related expenses	$ 2,800	$ 2,100	$ 800
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period of recognition for unrecognized compensation expense	1 year 7 months 6 days
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense related to non-vested stock awards	$ 30,800

Stock-Based Compensation - Comp

Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 25,406	$ 21,019	$ 13,252
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,665	2,012	1,162
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	4,434	3,372	2,332
Sales and marketing
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	6,438	6,009	3,497
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 11,869	$ 9,626	$ 6,261

Stock-Based Compensation - Esti

Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Risk-free interest rate	0.48%	1.18%	2.51%
Expected option life (in years)	4 years 11 months 26 days	5 years 1 month 13 days	5 years 8 months 4 days
Volatility rate	54.00%	41.00%	39.00%
Dividend rate	0.00%	0.00%	0.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Status of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Beginning balance, (in shares)	760	944	1,877
Granted, number of shares (in shares)	58	145	169
Exercised (in shares)	(90)	(317)	(1,091)
Forfeited (in shares)	(6)	(12)	(11)
Ending balance, (in shares)	722	760	944
Vested and expected to vest, (in shares)	709
Exercisable, (in shares)	448
Weighted-average exercise price per share
Beginning balance (in dollars per share)	$ 46.95	$ 30.63	$ 21.53
Granted (in dollars per share)	232.75	96.34	59.18
Exercised (in dollars per share)	38.28	21.03	19.22
Forfeited (in dollars per share)	94.44	43.34	49.71
Ending balance (in dollars per share)	62.71	$ 46.95	$ 30.63
Vested and expected to vest (in dollars per share)	61.35
Exercisable (in dollars per share)	$ 34.51
Weighted-average remaining contractual term (in years) and Aggregate intrinsic value
Weighted- average remaining contractual term, outstanding (in years)	6 years 7 days
Weighted- average remaining contractual term, vested and expected to vest (in years)	5 years 11 months 23 days
Weighted- average remaining contractual term, exercisable (in years)	4 years 10 months 28 days
Aggregate intrinsic value, outstanding	$ 59,339
Aggregate intrinsic value, vested and expected to vest	58,881
Aggregate intrinsic value, available for future grant	$ 45,376

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Status of Stock Awards Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Granted (in dollars per share)	$ 232.75	$ 96.34	$ 59.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning Balance (in shares)	878	786	676
Granted (in shares)	137	235	279
Vested (in shares)	(414)	(123)	(148)
Forfeited (in shares)	(14)	(20)	(21)
Ending Balance (in shares)	587	878	786
Weighted-average exercise price per share
Beginning Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 59.60	$ 41.88	$ 30.75
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	188.06	101.20	59.75
Exercised (in dollars per share)	38.28	21.03	19.22
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	49	26.58	24.26
Forfeited (in dollars per share)	94.44	43.34	49.71
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	106.11	58.32	43.90
Ending Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 95.81	$ 59.60	$ 41.88

Earnings Per Share - Computatio

Earnings Per Share - Computation of earnings per share (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income (Loss) Attributable to Parent	$ 704,226	$ 810,287	$ 72,921
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	0	445	1,848
Net Income (Loss) Available to Common Stockholders, Diluted	$ 704,226	$ 810,732	$ 74,769
Basic weighted-average common shares outstanding	42,078	42,124	40,860
Dilutive potential shares issuable from Convertible Notes	0	295	1,062
Dilutive potential shares issuable from stock options and unvested RSUs	796	1,172	1,189
Shares used in diluted per share calculation	42,874	43,591	43,111
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	153	10	199
Retained earnings
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Income (Loss) Attributable to Parent	$ 704,226	$ 810,287	$ 72,921

Earnings Per Share - Weighted-a

Earnings Per Share - Weighted-average shares outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic weighted-average common shares outstanding	42,078	42,124	40,860
Dilutive potential shares issuable from Convertible Notes	0	295	1,062
Dilutive potential shares issuable from stock options and unvested RSUs	796	1,172	1,189
Diluted weighted-average common shares outstanding, if-converted	42,874	43,591	43,111
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	153	10	199

Commitments and Contingencies -

Commitments and Contingencies - Components of Lease Expense and Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Finance Lease, Right-of-Use Asset, Amortization	$ 282	$ 303
Finance Lease, Interest Expense	657	877
Finance Lease, Cost	939	1,180
Operating Lease, Cost	15,361	11,236
Lease, Cost	16,300	12,416
Operating Lease, Payments	12,347	10,801
Finance Lease, Interest Payment on Liability	657	877
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	37,349	15,271
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 0	$ 0

Commitments and Contingencies_2

Commitments and Contingencies - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2022	$ 15,468
Operating Leases, 2023	15,529
Operating Leases, 2024	15,639
Operating Leases, 2025	15,736
Operating Leases, 2026	16,057
Operating Leases, Thereafter	116,835
Operating Leases, Minimum Payments, Total	195,264
Lease Obligation, 2020	272
Lease Obligation, 2021	297
Lease Obligation, 2022	99
Lease Obligation, 2023	0
Lease Obligation, 2024	0
Lease Obligation, Thereafter	0
Lease Obligation, Minimum Payments, Total	668
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	38,366
Finance Lease, Liability, Undiscounted Excess Amount	32
Less: tenant improvement allowance (receipt anticipated in 2022) , operating	(18,303)
Less: tenant improvement allowance (receipt anticipated in 2022), finance	0
Operating Lease, Liability	138,595
Finance Lease, Liability	636
Operating Lease, Liability, Current	(10,039)	$ (7,799)
Finance Lease, Liability, Current	(275)
Operating lease liabilities - non-current	128,556	$ 100,706
Finance Lease, Liability, Noncurrent	$ 361
Operating Lease, Weighted Average Remaining Lease Term	11 years 8 months 12 days
Finance Lease, Weighted Average Remaining Lease Term	3 years 3 months 18 days
Operating Lease, Weighted Average Discount Rate, Percent	4.00%
Finance Lease, Weighted Average Discount Rate, Percent	4.00%
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other non-current liabilities

Commitments and Contingencies_3

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Aug. 17, 2021USD ($)	Jul. 24, 2021USD ($)	Dec. 31, 2021USD ($)buildingoption	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Other Commitments [Line Items]
Number of buildings leased | building			3
Number of buildings | building			4
Number of additional terms to extend the lease | option			2
Renewal term			5 years
Purchase commitment			$ 3,400
Royalty Expense			2,000	$ 2,400	$ 1,100
Operating Lease, Liability			138,595
Minimum
Other Commitments [Line Items]
Master agreement, annual payment		$ 70,000
Maximum
Other Commitments [Line Items]
Master agreement, annual payment		$ 75,000
Partnership, McKellar San Diego Facility
Other Commitments [Line Items]
Payments to Acquire Partners Interest in Real Estate Partnership, Net of Cash Acquired	$ 28,900
Lease payments			600	$ 1,000	$ 1,000
Rutherford
Other Commitments [Line Items]
Operating Lease, Liability			$ 39,400

Commitments and Contingencies_4

Commitments and Contingencies - Contingent Consideration (Acquisitions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition, Contingent Consideration [Line Items]
Current portion of contingent consideration	$ 5,986	$ 5,987
Contingent consideration non-current portion	87	5,909
Fair Value, Inputs, Level 3
Business Acquisition, Contingent Consideration [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	$ 217	$ 1,405	$ 1,467

Segment, Revenue and Geograph_3

Segment, Revenue and Geographic Information - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)	Dec. 31, 2019
Revenue, Major Customer [Line Items]
Number of reportable segments | segment	1
Customer Concentration Risk | Sales | Non-US
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	17.00%	13.00%	33.00%
Customer Concentration Risk | Sales | CHINA
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	3.00%	4.00%	13.00%
Geographic Concentration Risk | Non-US
Revenue, Major Customer [Line Items]
Accounts receivable	$ 53.5	$ 18.6
Product Concentration Risk | Sales | Influenza Products
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	4.00%	8.00%	26.00%
Credit Concentration Risk
Revenue, Major Customer [Line Items]
Accounts receivable	$ 267.3	$ 411.7

Segment, Revenue and Geograph_4

Segment, Revenue and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenue (Detail) - Sales - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
A
Revenue, Major Customer [Line Items]
Sales percentage	24.00%	29.00%	13.00%
B
Revenue, Major Customer [Line Items]
Sales percentage	9.00%	16.00%	18.00%
C
Revenue, Major Customer [Line Items]
Sales percentage	9.00%	13.00%	5.00%
D
Revenue, Major Customer [Line Items]
Sales percentage	7.00%	10.00%	15.00%
Customer A, B, C, & D
Revenue, Major Customer [Line Items]
Sales percentage	49.00%	68.00%	51.00%

Segment, Revenue and Geograph_5

Segment, Revenue and Geographic Information - Long-lived Assets (Excluding Intangible Assets) and Total Net Revenue (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 349,202	$ 110,481
Revenue from Contract with Customer, Including Assessed Tax	1,698,551	1,661,668	$ 534,890
Federal
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	347,132	108,375
Revenue from Contract with Customer, Including Assessed Tax	1,415,413	1,452,329	358,381
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	2,070	2,106
Revenue from Contract with Customer, Including Assessed Tax	$ 283,138	$ 209,339	$ 176,509

Segment, Revenue and Geograph_6

Segment, Revenue and Geographic Information - Consolidated Net Product Revenues by Disease State (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 1,698,551	$ 1,661,668	$ 534,890
Infectious Disease
Segment Reporting Information [Line Items]
Revenues	1,197,459	1,144,831	191,736
Cardiac Immunoassay
Segment Reporting Information [Line Items]
Revenues	255,788	242,933	266,505
Specialized Diagnostic Solutions
Segment Reporting Information [Line Items]
Revenues	44,817	50,940	54,933
Molecular Diagnostic Solutions
Segment Reporting Information [Line Items]
Revenues	$ 200,487	$ 222,964	$ 21,716

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 84,778	$ 130,908
Assets, Fair Value Disclosure	275,015	200,027
Derivative liabilities	269	3,061
Money Market Funds, at Carrying Value	211,321	200,003
Total marketable securities	63,610	0
Derivative
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	84
Derivative liabilities	269
Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	6,073	11,896
Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	78,436	115,951
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	204,672	200,003
Money Market Funds, at Carrying Value	204,672	200,003
Total marketable securities	0	0
Level 1 | Derivative
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	0	0
Derivative liabilities	0	0
Level 1 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 1 | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	78,705	119,012
Assets, Fair Value Disclosure	70,343	24
Money Market Funds, at Carrying Value	6,649	0
Total marketable securities	63,610	0
Level 2 | Derivative
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	84	24
Derivative liabilities	269	3,061
Level 2 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Level 2 | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	78,436	115,951
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	6,073	11,896
Assets, Fair Value Disclosure	0	0
Money Market Funds, at Carrying Value	0	0
Total marketable securities	0	0
Level 3 | Derivative
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Asset	0	0
Derivative liabilities	0	0
Level 3 | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	6,073	11,896
Level 3 | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accretion of interest on deferred consideration	$ 4,485	$ 6,569	$ 8,224
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	217	$ 1,405	$ 1,467
Consideration B | BNP Business
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Amount Of Installment Payment	$ 48,000

Fair Value Measurement - Change

Fair Value Measurement - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) - Level 3 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 11,896	$ 16,535	$ 19,112
Cash payments	(6,040)	(6,044)	(4,044)
Change in estimated fair value, recorded in general and administrative expenses	(217)	(1,405)	(1,467)
Ending balance	$ 6,073	$ 11,896	$ 16,535

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Compensation Related Costs [Abstract]
Pay contributed by employer	50.00%
Pay contributed by employee	6.00%
Contribution to 401 (K) Plan	$ 3.8	$ 3.1	$ 2.5

Foreign Currency Hedges (Detail

Foreign Currency Hedges (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash Flow Hedging | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liability, Notional Amount	$ 17,629	$ 38,435
Derivative Liability, Fair Value, Gross Liability	139	2,819
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Asset, Notional Amount	0
Derivative, Fair Value, Net	84
Prepaid Expenses and Other Current Assets | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Notional Amount	0	18,160
Derivative Liability, Notional Amount	15,809	23,120
Derivative Asset, Fair Value, Gross Asset	0	24
Derivative Liability, Fair Value, Gross Liability	130	242
Prepaid Expenses and Other Current Assets | Cash Flow Hedging | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Notional Amount	0	0
Derivative Asset, Fair Value, Gross Asset	84	$ 0
Other Current Liabilities
Derivative [Line Items]
Derivative Asset, Notional Amount	17,629
Derivative, Fair Value, Net	$ 139

Pending Business Combination (D

Pending Business Combination (Details) - USD ($)	Dec. 22, 2021	Feb. 09, 2022
Topco
Business Acquisition [Line Items]
Expected ownership percentage by parent	62.00%
Topco | Ortho
Business Acquisition [Line Items]
Expected ownership percentage by noncontrolling owners	38.00%
Ortho Acquisition
Business Acquisition [Line Items]
Shares to be issued per acquire share	1
Consideration to be transferred	$ 4,300,000,000
Expected payments to acquire businesses	1.75
Ortho
Business Acquisition [Line Items]
Expected long-term debt	$ 2,100,000,000
Topco | Ortho Acquisition
Business Acquisition [Line Items]
Shares to be issued per acquire share	0.1055
Cash to be paid per acquire share	$ 7.14
Subsequent Event | Ortho Acquisition
Business Acquisition [Line Items]
Closing price		$ 97.64

Consolidated Valuation and Qu_2

Consolidated Valuation and Qualifying Accounts (Detail) - SEC Schedule, 12-09, Allowance, Credit Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period		$ 103,435	$ 15,960	$ 11,979
Additions charged to expense or as reductions to revenue	[1]	456,237	276,988	65,649
Deductions	[2]	(507,249)	(189,513)	(61,668)
Balance at end of period		$ 52,423	$ 103,435	$ 15,960
[1]	Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expense.
[2]	The deductions represent actual charges against the accrual described above.